Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 512
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goldstein, L. J. Articles by Davidson, N. Search for Related Content PubMed Articles by Goldstein, L. J. Articles by Davidson, N.

Abstract

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD

512

Background: AT is one of the most active regimens in ABC (response rates=44–83%). Methods: A Phase III Intergroup trial was completed to test adjuvant AT vs. AC. Women with 1–3 N + or N - and T-size > 1cm were randomized to four cycles of AT (60 mg/m²/60 mg/ m²) or AC (60 mg/m²/600 mg/m²) q 3 wk x 4. After chemotherapy, pts with ER + and/ or PR + received tam for 5 years. Patients were stratified by nodal, hormone receptor (ER+ PR+, ER+PR-, ER-PR+, ER-PR-, ER/PR unk) and menopausal status. The primary endpoint was DFS. With 2778 patients (including 10% ineligible), this study had 83% power to detect a 25% reduction in DFS failure hazard rate using AT(assuming a 78% 5-yr DFS on the AC arm). Results: 2952 pts were randomized between 7/30/98 and 1/21/00. 2889 were eligible and analyzable. Arms were balanced for age, hormone receptor, menopause, nodes, surgery, grade and T-size: median age 51; 64% ER +; 65% LN-; grade: 10% low, 38% int., 46% high; and median T-size - 2.0 cm. Febrile neutropenia occurred in 19%(AT) and 6%(AC). There were 3 treatment related deaths on the AT arm. There were 7 cases of MDS/AML on each arm. DFS/OS Results: As of 9/04, with a median follow-up of 53 mo, there were 197/1444 recurrences in the AT arm vs. 212/1445 in the AC arm and 104 deaths in the AT arm vs. 113 in the AC arm: HR (.95 CI) for OS = 1.09 (0.84–1.43), p=0.48. Conclusions: These results show a better than expected outcome with both regimens. At 53 mo. median follow-up, there is no difference in DFS or OS, although there are fewer events in the AT arm. Data for the subset analysis of prespecified stratifications: LN, menopause, and various ER/PR groups will be presented.

View larger version (12K): [in this window] [in a new window]

Abstract presentation from the 2005 ASCO Annual Meeting